Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710362 | 1.00 | HTT (0.49) | HTTTSHRAPOBEC3AAPOBEC3GNCOA1 | |
| SCHEMBL1003817 | 0.89 | TSHR (0.53) | HTTTSHRAPOBEC3AAPOBEC3GNCOA1 | |
| SCHEMBL18471225 | 0.84 | SMN1; SMN2 (0.49) | HTTTSHRAPOBEC3AAPOBEC3GSMN1; SMN2 | |
| SCHEMBL12659328 | 0.81 | NPC1 (0.45) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL29710249 | 0.81 | TTR (0.56) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL5631374 | 0.81 | TTR (0.56) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1505378 | 0.80 | TSHR (0.44) | HTTTSHRAPOBEC3AAPOBEC3GNCOA1 | |
| SCHEMBL29710347 | 0.76 | CA12 (0.48) | TSHRALDH1A1POLBMAPTKDM4E | |
| SCHEMBL19357846 | 0.76 | CA12 (0.48) | TSHRALDH1A1POLBMAPTKDM4E | |
| SCHEMBL482111 | 0.75 | CHRNA1 (0.50) | HTTTSHRAPOBEC3AAPOBEC3GSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| WO-2017158388-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | USP7, USP47, USP2 | HTT 3323/4885TSHR 4510/4885APOBEC3A 961/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | HTT 3323/4885TSHR 4510/4885APOBEC3A 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.